02:38:35 Europe / Stockholm

Prenumeration

2024-05-29 10:45:00

• Addressing a large patient group in need of new treatment alternatives
• Phase I to be concluded in 2024
• We initiate coverage with a fair value of SEK 10.81 per share

Chronic inflammation, such as rheumatoid arthritis, affects millions of people globally. Available treatment options are often insufficient and new approaches are much needed. Umeå-based Lipum develops SOL-116, a new way to treat inflammation. The company expects to conclude the phase I study by late 2024 and plans for the next development step.

Västra Hamnen initiates research coverage of Lipum with a fair value of SEK 10.81 per share. The full report is available here.